STAT+: Moderna CEO on what’s next after success in cancer vaccine

Coverage, in order

1. 16d ago
   first Science Magazine News indie

   Milestone cancer vaccine success leaves hard questions unanswered

   mRNA vaccine from Merck and Moderna slashes risk of melanoma’s return, but why remains unclear

2. 16d ago
   
   STAT Biotech indie

   STAT+: Moderna CEO on what’s next after success in cancer vaccine

   MADRID — Moderna CEO Stéphane Bancel had every reason to be smiling and happy on a brilliantly sunny Saturday afternoon here in Spain’s capital. In a couple of hours, a decade of the company’s research — boosted by a partnership with Merck — was going to culminate in the presentation of the first…

3. 14d ago
   
   WSJ Health mainstream

   Moderna’s CEO told The Wall Street Journal that his cancer vaccine’s data will get better with time, and that no one can easily copy the company’s work

   Stéphane Bancel defended his melanoma data and argued that rivals can’t easily copy the technology.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.